Eylea, Lucentis and Avastin are compared head to head. Eylea is best for patients with moderate vision loss or worse.
Tag: lucentis
A safety review and meta-analyses of bevacizumab and ranibizumab in age related macular degeneration: Off-label versus gold standard
Source: PLoS One
Area: News
The authors of this paper carried out a systematic review based on randomised controlled clinical trials (RCTs) to assess whether unlicensed therapy with bevacizumab is as safe as licensed therapy with ranibizumab for the t…
Avastin/Lucentis Update 47: Should the UK’s NICE Consider Adding Avastin to It’s Approved Drugs?
In a blog, appearing on the BMJ (British Medical Journal) Group Blogs, James Raftery, a health economist with several decades’ experience with the National Health Service (NHS) and a professor of health technology assessment at Southampton University, regularly writes about…
Avastin Just as Good as Lucentis
It’s official. Avastin is just as good as Lucentis for the treatment of wet macular degeneration. The results of this National Eye Institute study were released just a week ago. The study, Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)…
CATT Update 15: Preliminary Two-Year Safety Data Presented at ARVO
Two of the authors of the CATT Study, that was published in the NEJM last Thursday, Drs. Dan Martin and Maureen McGovern, presented additional information about the study at the opening day ARVO Meeting, to about 2000 eager attendees. As…
CATT Study Update 12: Status of WorldWide Studies
With the anticipated arrival of the one-year results of the CATT Study this Spring, I thought it would be appropriate to update where the other worldwide studies stand.During the Retina Subspecialty Day sessions, held prior to the recent 2010 AAO Meeti…
Treat and Extend Regimen Saves Money and Injections for AMD
Full Story →
Avastin/Lucentis Update 43: Secret Rebates Offered for Lucentis
First, Genentech refused to provide Lucentis for the CATT Study, being run by NEI/NIH to compare Avastin to Lucentis for AMD (Avastin/Lucentis Update 12); then they threatened to stop supplying Avastin to compounding pharmacies so that ophthalmologists…
Drugs for macular degeneration
(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of a…